KR20100075412A - 방사성 세포 표지자 - Google Patents
방사성 세포 표지자 Download PDFInfo
- Publication number
- KR20100075412A KR20100075412A KR1020090130673A KR20090130673A KR20100075412A KR 20100075412 A KR20100075412 A KR 20100075412A KR 1020090130673 A KR1020090130673 A KR 1020090130673A KR 20090130673 A KR20090130673 A KR 20090130673A KR 20100075412 A KR20100075412 A KR 20100075412A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- iodine
- hib
- reacting
- Prior art date
Links
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 26
- 238000002372 labelling Methods 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 79
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 31
- 239000011630 iodine Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 19
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims abstract description 13
- NJAKCIUOTIPYED-UHFFFAOYSA-N 4-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(I)C=C1 NJAKCIUOTIPYED-UHFFFAOYSA-N 0.000 claims abstract description 10
- REDSKZBUUUQMSK-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC.CCCC[Sn](CCCC)CCCC REDSKZBUUUQMSK-UHFFFAOYSA-N 0.000 claims abstract description 7
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims abstract description 5
- 229910052751 metal Inorganic materials 0.000 claims abstract description 5
- 239000002184 metal Substances 0.000 claims abstract description 5
- 229940055577 oleyl alcohol Drugs 0.000 claims abstract description 5
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 65
- ZKFRNBNJQLIUAC-UHFFFAOYSA-N hexadecyl 4-iodobenzoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C1=CC=C(I)C=C1 ZKFRNBNJQLIUAC-UHFFFAOYSA-N 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 8
- 210000001808 exosome Anatomy 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 239000000693 micelle Substances 0.000 claims description 5
- 229960000541 cetyl alcohol Drugs 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 16
- 239000003550 marker Substances 0.000 abstract description 8
- 230000009087 cell motility Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000033001 locomotion Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 18
- 239000002243 precursor Substances 0.000 description 16
- 238000003384 imaging method Methods 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- -1 122 I Chemical compound 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 6
- 235000009518 sodium iodide Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- VEXRMMJOMMTPKJ-ZVSIBQGLSA-N 1-methyl-3-[(e)-[(1e)-1-(methylcarbamothioylhydrazinylidene)propan-2-ylidene]amino]thiourea Chemical compound CNC(=S)N\N=C\C(\C)=N\NC(=S)NC VEXRMMJOMMTPKJ-ZVSIBQGLSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- NQGGSLIANNZKLR-UHFFFAOYSA-N CCCCCCCCCCCCCCCCOC(=O)C1=CC=C(C=C1)[Sn](CCCC)(CCCC)CCCC Chemical compound CCCCCCCCCCCCCCCCOC(=O)C1=CC=C(C=C1)[Sn](CCCC)(CCCC)CCCC NQGGSLIANNZKLR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical group CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- CEGXZKXILQSJHO-KODRXGBYSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanoyl fluoride Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)CC(F)=O CEGXZKXILQSJHO-KODRXGBYSA-N 0.000 description 1
- PFYBOLMZTAKFPE-UHFFFAOYSA-N 2-fluoro-3-hexadecylbenzoic acid Chemical compound CCCCCCCCCCCCCCCCC1=C(C(=CC=C1)C(=O)O)F PFYBOLMZTAKFPE-UHFFFAOYSA-N 0.000 description 1
- SGVMUNLMYOTMRP-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)C1=C(C(=O)O)C=CC(=C1)I.IC1=C(C(=O)O)C=CC=C1 Chemical compound C(CCCCCCCCCCCCCCC)C1=C(C(=O)O)C=CC(=C1)I.IC1=C(C(=O)O)C=CC=C1 SGVMUNLMYOTMRP-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- YWJGSUNEZDRNLW-UHFFFAOYSA-N IC1=C(C(=O)OCCCCCCCCCCCCCCCC)C=CC=C1 Chemical compound IC1=C(C(=O)OCCCCCCCCCCCCCCCC)C=CC=C1 YWJGSUNEZDRNLW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- AMZMQXJQIYKBJU-UHFFFAOYSA-N iodo benzoate Chemical compound IOC(=O)C1=CC=CC=C1 AMZMQXJQIYKBJU-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910001511 metal iodide Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (16)
- 제 1항 내지 제 4항 중 어느 한 항에 있어서,상기 X는 122I, 123I, 124I, 125I, 131I 및 132I로 이루어진 요오드의 방사성 동위원소 군으로부터 선택되는 것을 특징으로 하는 방사성 표지 화합물.
- 제 6항에 있어서, X는 122I, 123I, 124I, 125I, 131I 및 132I로 이루어진 요오드의 방사성 동위원소 군으로부터 선택되는 조성물.
- 제 8항 또는 제 9항에 있어서, 요오드는 122I, 123I, 124I, 125I, 131I 및 132I로 이루어진 요오드의 방사성 동위원소 군으로부터 선택되는 방법.
- 제 1항 내지 제 5항 중 어느 한 항의 방사성 표지 화합물에 의해 표지된 세포.
- 제 1항 내지 제 5항 중 어느 한 항의 방사성 표지 화합물에 의해 표지된 리포좀.
- 제 1항 내지 제 5항 중 어느 한 항의 방사성 표지 화합물에 의해 표지된 엑소좀.
- 제 1항 내지 제 5항 중 어느 한 항의 방사성 표지 화합물에 의해 표지된 마이셀.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080133578 | 2008-12-24 | ||
KR20080133578 | 2008-12-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100075412A true KR20100075412A (ko) | 2010-07-02 |
KR101130737B1 KR101130737B1 (ko) | 2012-03-28 |
Family
ID=42288322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090130673A KR101130737B1 (ko) | 2008-12-24 | 2009-12-24 | 방사성 세포 표지자 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101130737B1 (ko) |
WO (1) | WO2010074532A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019216477A1 (ko) * | 2017-06-02 | 2019-11-14 | 경북대학교 산학협력단 | 엽산 수용체 타겟팅 종양 진단 방사성 프로브의 개발 및 응용 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101469156B1 (ko) * | 2013-05-31 | 2014-12-04 | 경북대학교 산학협력단 | Pet/mr/광학 이미지 삼중 조영제 |
KR101523249B1 (ko) * | 2014-05-22 | 2015-05-27 | 서울대학교산학협력단 | 엑소좀을 방사성 물질로 표지하는 방법 및 그 용도 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4791097A (en) * | 1987-03-09 | 1988-12-13 | Finetex, Inc. | Benzoic acid esters and their use |
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
JP2002516883A (ja) * | 1998-06-02 | 2002-06-11 | ザ ダウ ケミカル カンパニー | 近接照射療法のための放射性ヨウ素化フェノール |
KR100338652B1 (ko) * | 1999-04-15 | 2002-05-30 | 장인순 | 붕소페닐알라닌의 방사요오드 표지화합물 |
-
2009
- 2009-12-24 WO PCT/KR2009/007780 patent/WO2010074532A2/ko active Application Filing
- 2009-12-24 KR KR1020090130673A patent/KR101130737B1/ko active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019216477A1 (ko) * | 2017-06-02 | 2019-11-14 | 경북대학교 산학협력단 | 엽산 수용체 타겟팅 종양 진단 방사성 프로브의 개발 및 응용 |
US11266755B2 (en) | 2017-06-02 | 2022-03-08 | Kyungpook National University Industry-Academic Cooperation Foundation | Development and application of tumor diagnostic radioactive probe targeting folic acid receptor |
Also Published As
Publication number | Publication date |
---|---|
WO2010074532A9 (ko) | 2010-11-04 |
WO2010074532A3 (ko) | 2010-09-10 |
KR101130737B1 (ko) | 2012-03-28 |
WO2010074532A2 (ko) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220088229A1 (en) | Psma-binding agents and uses thereof | |
EP3400229B1 (en) | 18/19f-labelled compounds which target the prostate specific membrane antigen | |
CA2473289C (en) | Asymmetric urea compounds useful as naaladase and psma imaging agents | |
JP5341136B2 (ja) | 腫瘍画像化のためのアミノ酸アナログ | |
Michelot et al. | Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma | |
US9096647B2 (en) | Simplified one-pot synthesis of [18F]SFB for radiolabeling | |
WO2015178618A1 (ko) | 엑소좀을 방사성 물질로 표지하는 방법 및 그 용도 | |
KR101130737B1 (ko) | 방사성 세포 표지자 | |
CN115974962A (zh) | 一种fap靶向的探针及其制备方法和应用 | |
WO1999020316A1 (en) | Single photon-emitting radiotraces and methods for their use | |
US20180064742A1 (en) | Pet imaging tracer for imaging prostate cancer | |
JPH09176179A (ja) | グルコースまたはマンノース誘導体、および該誘導体を含有する放射性診断剤 | |
EP3096799B1 (en) | Labeled molecular agents for imaging cystine/glutamate antiporter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150217 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160318 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170203 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180220 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190304 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20200302 Year of fee payment: 9 |